ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
DiaCarta Receives CE/IVD for its New COVID 19 Screening Test that Identifies Delta Plus and New Variants prnasia
September 13, 2021DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced that its new QuantiVirus? SARS-CoV-2 Variant Detection Test received the CE/IVD marking and therefore... -
DiaCarta Receives CE/IVD for its New COVID 19 test that Identifies Delta Plus and New Variants prnewswire
August 13, 2021DiaCarta Inc., today announced that its new QuantiVirus? SARS-CoV-2? Variant Detection Test received the CE/IVD marking and therefore, can now be commercialized within the EU and rest of the world.
Pharma Sources Insight January 2025
